--- title: "BPC-157 Deep Research Review" slug: "bpc-157" type: "research" url: "https://peptidesciencethailand.com/research/bpc-157" lastReviewed: "2026-04-01" overallScore: "2.5/5" verdict: "Preclinical-promising, clinically unproven" description: "Does BPC-157 actually heal tendons and gut tissue? 16 studies graded, zero human RCTs published. Honest 2.5/5 evidence verdict, side effects, dosing reality." --- # BPC-157 — Deep Research Review **Full name:** Body Protection Compound-157 **Sequence:** GEPPPGKPADDAGLV **Molecular weight:** ~1419 Da **Overall evidence score:** 2.5/5 **Verdict:** Preclinical-promising, clinically unproven ## Executive Summary BPC-157 is a 15-amino-acid synthetic peptide that has been studied mainly in animals and cell models for tissue repair, gastrointestinal protection, and broader organ protection effects. The preclinical literature contains many positive findings across many models, but this is not the same thing as "clinically proven", and the mechanistic story is still incomplete. Human evidence is thin and low quality: a retrospective chart review of knee injections (uncontrolled, subjective outcomes), a small pilot study for interstitial cystitis (12 participants, no control group), and a two-person pilot safety study of IV infusion. A Phase I oral safety/PK study (NCT02637284) was registered but no results are posted in the public record. From a regulatory standpoint, BPC-157 is not an approved human medicine; it is prohibited in sport under the S0 category by WADA, and the U.S. FDA explicitly raises safety concerns around immunogenicity risk, peptide impurities, and lack of safety information. ## Editorial Position BPC-157 is preclinical-promising but clinically unproven; most confident online claims are ahead of human evidence; and safety/quality risks are not solved by enthusiasm. ## What It Is BPC-157 is described in the literature as a stable gastric pentadecapeptide, typically written as the amino-acid sequence GEPPPGKPADDAGLV (molecular weight ~1419). It is repeatedly framed as originating from fragments identified in gastric juice research, and was developed in the context of gastrointestinal cytoprotection ideas (protecting mucosa and then extending that concept to other tissues). ## Mechanisms ### Angiogenesis and endothelial/NO signalling *Verdict:* Clearest independent mechanistic support A 2017 study reports pro-angiogenic effects associated with increased expression and internalisation of VEGFR2 and activation of VEGFR2-Akt-eNOS signalling, with angiogenesis assays and improved blood flow recovery in a rat hind-limb ischaemia model. A 2020 paper reports that BPC-157 modulates vasomotor tone in isolated aorta in a concentration- and nitric-oxide-dependent manner, and suggests NO generation via a Src-caveolin-1-eNOS pathway. ### Tendon-cell and fibroblast biology *Verdict:* Suggestive, not dispositive A cell study in tendon fibroblasts reports that BPC-157 up-regulates growth hormone receptor expression (dose- and time-dependent), and that growth hormone then increases proliferation signals with downstream JAK2 activation. ### Anti-inflammatory and cytokine modulation *Verdict:* Demonstrated in animal models; human relevance unconfirmed Multiple animal studies report that BPC-157 modulates key pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, with effects observed in colitis, adjuvant arthritis, and sepsis models. The peptide appears to attenuate excessive inflammatory signalling without complete immunosuppression, suggesting a modulatory rather than purely suppressive role. ### Cytoprotection and organoprotection *Verdict:* Broad preclinical signal; mechanism not fully resolved BPC-157 has been studied in models of gastric, hepatic, cardiac, and renal injury, often framed around Robert's concept of adaptive cytoprotection — the idea that the GI tract can mount protective responses to sub-damaging stimuli. The peptide has shown protective effects against NSAID-induced gastric lesions, ethanol-induced damage, and ischaemia-reperfusion injury across multiple organ systems in rats. ### Nitric oxide system regulation *Verdict:* Consistent preclinical signal across multiple models Multiple studies suggest BPC-157 interacts with the nitric oxide (NO) system in a modulatory fashion — counteracting both NO-excess and NO-deficiency states in animal models. The peptide has been shown to activate eNOS via Src-caveolin-1-eNOS signalling, modulate vasomotor tone in isolated aorta preparations, and interact with L-NAME (NOS inhibitor) and L-arginine (NO precursor) pathways in fistula healing, blood pressure, and GI protection models. ### Multiple proposed pathways *Verdict:* Claim, not resolved mechanism Reviews describe interactions across neurotransmitters and the gut-brain axis, and repeatedly emphasise stability in gastric juice and broad system effects. These are hypothesis-generating narratives, not clinical proof, and they often synthesise many animal models without resolving bias, replication, or real-world dosing comparability. ## Animal Studies | Domain | Species | Dose | Outcome | Limitation | | --- | --- | --- | --- | --- | | Achilles tendon transection | Rat | Not detailed in early paper | Improved Achilles tendon healing and in-vitro tendocyte stimulation | Rodent tendon healing; does not establish effect size or reliability in human tendon pathology. | | MCL transection | Rat | 10 ug/kg or 10 ng/kg i.p. daily; topical 1.0 ug/g cream; oral 0.16 ug/mL water | Multiple routes effective for ligament healing outcomes | Single species, surgically created injury, controlled environment; positive preclinical result does not inform human dosing, safety, or comparative effectiveness. | | Quadriceps muscle transection | Rat | 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. | Improved biomechanical load-to-failure, functional recovery, histological regeneration over 72 days | Dramatic results in rodents can be real and still fail to translate, especially when human injury types, rehabilitation forces, and comorbidities differ. | | Colocutaneous fistula | Rat | 10 ug/kg or 10 ng/kg oral water or i.p. | Accelerated closure and improved functional leakage outcomes; NO-system interaction tested | Fistula models are far from the everyday leaky gut claim; repair in rats does not validate oral self-use or predict long-term human safety. | | Neuroleptic gastric injury + catalepsy | Mouse/Rat | 10 ug/kg or 10 ng/kg i.p. | Attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions | These are pharmacology models; they support biological activity, not broad clinical claims like heals the gut lining in humans. | | Systemic organ protection (I/R injury) | Rat | Standard research doses | Examined distant-organ injury (kidney/liver/lung) following skeletal muscle ischaemia-reperfusion | Systemic I/R models are complex; generalising them to human wellness claims is a major leap without controlled human clinical work. | ## Human Studies ### Retrospective knee pain injection study **Type:** Uncontrolled retrospective chart review **Participants:** 16 patients (of 17 treated) **Dose:** Intra-articular; 2000 ug/mL concentration, typical dose 2 cc (4 mg) **Outcome:** 11/12 improvement with BPC-157 alone; 3/4 improvement with BPC-157 + thymosin-B4 **Limitations:** Subjective outcomes, only minority had pre-procedure MRI, no randomisation, no control group, heterogeneous diagnoses, high risk of placebo effects and selection bias. ### Interstitial cystitis pilot **Type:** Single-site pilot, no control group **Participants:** 12 women **Dose:** Intravesical injection, total 10 mg **Outcome:** 10/12 complete resolution, 2/12 reported 80% improvement, no adverse events **Limitations:** Small sample, lack of sham control. The limitations section of the paper itself explicitly notes these issues. ### IV infusion safety pilot **Type:** Pilot safety study **Participants:** 2 healthy adults **Dose:** IV infusion up to 20 mg **Outcome:** No adverse effects reported; well tolerated **Limitations:** n=2 can only support a narrow statement. Cannot establish general safety, rare adverse events, long-term risks, or safety of non-IV routes. ### Phase I oral safety/PK trial **Type:** Registered Phase I RCT (NCT02637284) **Participants:** Planned: 42 healthy volunteers **Dose:** Oral tablets 1 mg BPC-157 (Bepecin/PCO-02); single-dose cohorts (1, 3, or 6 tablets) and multiple-dose (3 tablets q8h x 2 weeks) **Outcome:** Unknown status; no results posted in public record **Limitations:** A registered trial without public results is evidence of investigation, not evidence of efficacy or safety. ## Hype vs Evidence | Claim | Social Media Implies | Evidence Supports | Verdict | | --- | --- | --- | --- | | Heals tendon tears / ligament ruptures fast | Direct repair of human tears; faster return to sport | Multiple rodent surgical injury models show improved healing at ng/kg-ug/kg dosing; human evidence limited to uncontrolled knee pain chart review (not tendon tears per se); registered hamstring strain trial exists but no outcomes yet. | Preclinical-promising; clinically unproven | | Fixes knee pain and builds cartilage | Regenerates cartilage; avoids surgery | One uncontrolled retrospective injection study reports symptom improvement, but no control group, limited imaging, and subjective endpoints prevent efficacy conclusions. | Not proven; high bias risk | | Heals the gut / leaky gut | Reliable human GI repair from oral dosing | Rat GI models (fistula healing, ulcer protection) show biological activity; human ulcerative colitis work referenced historically but public trial results not visible as full peer-reviewed clinical paper. | Animal evidence exists; human proof missing | | Neuroprotective / dopamine / brain repair | Cognitive enhancement; treatment for neurological disease | Animal pharmacology signals exist (catalepsy attenuation; CNS-focused reviews), but there is no robust human neurological outcomes dataset. | Speculative in humans | | Completely safe / no side effects | Safe enough for self-injection | Regulators explicitly cite insufficient safety information and immunogenicity/impurity concerns; human datasets are tiny (n=2 IV safety). | Unsupported; safety is uncertain | | Legal and standard in clinics | Treated like routine peptide therapy | WADA prohibits; FDA flags compounding risk; anti-doping bodies warn of non-approved status and unknown dosing. | Regulatory risk is real | ## Evidence Ratings | Domain | Score | Rationale | | --- | --- | --- | | Tendon/ligament/muscle repair | 2.5/5 | Strong animal signals in several models and doses; human efficacy evidence is uncontrolled, and registry data lack posted results. | | Knee pain | 2/5 | Human data exists but is retrospective, subjective, heterogeneous, and uncontrolled. | | GI healing / mucosal protection | 2/5 | Demonstrated activity in animal GI injury/repair models; clinical efficacy not established from public peer-reviewed trials. | | Neuro/CNS | 2/5 | Signals exist in animal work; no meaningful controlled human neurological outcomes dataset. | | Systemic/organ protection | 2/5 | Preclinical models and plausible endothelial mechanisms; no human controlled outcomes. | | Safety in humans | 2/5 | Small studies do not show obvious acute toxicity but cannot establish safety; FDA explicitly highlights lack of safety info and potential risks. | ## Safety & Regulatory ### Pharmacokinetics Prototype BPC-157 showed short elimination half-life (<30 minutes) in rats and beagle dogs after IV and IM dosing, with rapid Tmax (~9 minutes) after IM injections; IM bioavailability ~14-19% in rats and ~45-51% in dogs. Using radiolabelled BPC-157, total radioactivity suggested extensive metabolism/decomposition; urinary excretion dominant, with higher levels later in kidney and liver. The "it's stable in the stomach so it must work orally" story is incomplete: stability and bioavailability are not the same, and animal PK does not substitute for human PK. ### Safety Statement The human clinical literature is too small to establish safety: the knee pain chart review, the interstitial cystitis pilot, and the IV n=2 study are not a safety database. Animal studies and reviews often assert wide safety margins, but the highest-integrity approach is to anchor safety claims to actual regulatory statements. ### Regulatory Points **Thai FDA (อย.) — Not a registered pharmaceutical** BPC-157 is not registered as a pharmaceutical product with the Thai Food and Drug Administration (สำนักงานคณะกรรมการอาหารและยา / อย.). It is not listed in the Thai National List of Essential Medicines and has no approved therapeutic indication in Thailand. Peptide products available through Thai clinics and wellness providers operate in a regulatory grey area without standardised oversight for this specific compound. Source: https://www.fda.moph.go.th/ **U.S. FDA — Category 2 → reclassification announced but not completed** BPC-157 was classified as a Category 2 bulk drug substance with cited safety risks (immunogenicity, impurities, insufficient safety data). In February 2026, U.S. HHS Secretary Kennedy announced that approximately 14 peptides including BPC-157 would be moved from Category 2 to Category 1 (eligible for compounding). As of late March 2026, this reclassification has not been formally completed by the FDA. Important: Category 1 compounding eligibility is not FDA approval, and U.S. regulatory developments have no bearing on Thai regulatory status. Source: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks **Grey-Market Sourcing (Thailand) — Variable quality; no batch-release guarantees** In Thailand, peptides including BPC-157 are available through clinics, wellness providers, and online sellers with highly variable quality assurance. Without standardised regulatory oversight for this compound, there are no batch-release testing guarantees, no mandatory purity certificates, and no assurance of correct peptide identity or concentration. Contamination risk, sub-potency, and misidentification are real concerns when sourcing from unregulated suppliers. Source: https://www.fda.moph.go.th/ **WADA — Prohibited (S0 Non-Approved Substances)** Named as an example under S0 on the 2026 Prohibited List (valid 1 January 2026). Added by name in 2022 after re-evaluation. Source: https://www.wada-ama.org/en/news/wadas-2022-prohibited-list-now-force **USADA — Prohibited; unknown safe dose** Emphasises BPC-157 is prohibited and not approved for human clinical use; safe dosing is unknown because it has not been extensively studied in humans. Source: https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/ **OPSS (U.S. DoD) — Unapproved drug** Describes BPC-157 as an unapproved drug; safety/effectiveness have not been thoroughly evaluated in humans. Source: https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products ## Dosing (Research Doses Only) > No approved human dosing protocol exists for BPC-157 from any regulatory authority. The following summarises doses reported in published research. These are not recommendations. ### Animal Doses | Route | Dose | Context | | --- | --- | --- | | Intraperitoneal (i.p.) | 10 µg/kg or 10 ng/kg body weight, daily | Most common dose range across rat studies (tendon, ligament, muscle, GI models) | | Oral (drinking water) | 0.16 µg/mL in drinking water ad libitum | Used in rat ligament and fistula healing studies | | Topical (cream) | 1.0 µg/g cream applied locally | Used in rat ligament healing studies | ### Human Doses Reported | Route | Dose | Context | | --- | --- | --- | | Intra-articular injection | 4 mg (2 cc of 2000 µg/mL) | Retrospective knee pain chart review (uncontrolled, 16 patients) | | Intravesical injection | 10 mg total | IC pilot study (12 participants, no control group) | | IV infusion | Up to 20 mg | Safety pilot (n=2 only) | | Oral tablets | 1 mg per tablet (1–6 tablets per dose) | Registered Phase I trial (NCT02637284); no results posted | ## Research Concentration Note A substantial proportion of the BPC-157 preclinical literature originates from one research group led by Predrag Sikirić at the University of Zagreb, Croatia. While prolific output from a single group is not inherently a flaw, it is a standard scientific concern: independent replication by other laboratories is limited, and the field would benefit from more diverse research groups reproducing key findings. ## Open Questions / Unknowns - No published human RCTs for tendon/ligament/muscle healing outcomes. - No robust human pharmacokinetics by route (oral vs subcutaneous vs intra-articular), and animal PK does not solve this. - No credible long-term safety database; rare harms cannot be ruled out from n=2 or n=12 studies. - No manufacturing-quality reassurance in grey markets; FDA explicitly flags peptide impurity/characterisation complexities and limited safety information. - Mechanism remains incomplete: endothelial/angiogenic signalling is plausible, but a unifying target that predicts who benefits, who doesn't, and who is harmed is not established. - Most preclinical BPC-157 studies originate from a single research group (University of Zagreb); independent replication by other laboratories is limited. ## Frequently Asked Questions ### What are the proven benefits of BPC-157? BPC-157 shows promising results in animal studies for tissue repair, gastrointestinal protection, and organ protection. However, human clinical evidence is extremely limited. No published randomised controlled trials exist for common claims like tendon repair, gut healing, or neuroprotection. The overall evidence score is 2.5 out of 5. ### Is BPC-157 safe? Safety is uncertain. The human safety database is extremely small (studies with only 2–16 participants). The U.S. FDA explicitly cites potential safety risks including immunogenicity concerns and peptide impurities. It is prohibited in sport by WADA under the S0 category. ### What are the side effects of BPC-157? Due to the very small number of human studies, a comprehensive side effect profile has not been established. The limited studies report no obvious acute toxicity, but regulatory agencies warn about immunogenicity risk, peptide-related impurities, and insufficient safety information to determine whether it would cause harm. ### Does BPC-157 heal tendons? Multiple rodent studies show improved tendon and ligament healing outcomes. However, human evidence is limited to one uncontrolled retrospective chart review of knee injections (16 patients, no control group). No published human RCTs exist for tendon or ligament healing. ### Is BPC-157 legal? BPC-157 is not a registered pharmaceutical in Thailand (อย.) and is not an approved human medicine by any major regulator internationally. It is prohibited in sport by WADA under S0 (Non-Approved Substances). In the U.S., it was classified as a Category 2 bulk drug substance; a reclassification was announced in February 2026 but has not been formally completed. In Thailand, peptide products are available through clinics and online sellers but operate in a regulatory grey area. ### Does BPC-157 heal the gut? Rat gastrointestinal models show biological activity for fistula healing and ulcer protection. However, human clinical proof of gut healing is missing. No peer-reviewed clinical trial results demonstrate GI repair efficacy in humans from oral dosing. ### How does BPC-157 work? The clearest mechanistic evidence involves pro-angiogenic effects through VEGFR2-Akt-eNOS signalling, promoting blood vessel formation and blood flow. Additional proposed pathways include tendon fibroblast stimulation, anti-inflammatory cytokine modulation (TNF-α, IL-1β, IL-6), cytoprotection of organ tissues, and nitric oxide system regulation. However, a unifying mechanism is not yet established, and 'multiple pathways' can also mean the mechanism has not been pinned down. ### Where does BPC-157 research come from? A substantial proportion of BPC-157 preclinical research originates from one laboratory group led by Predrag Sikirić at the University of Zagreb, Croatia. While their work is extensive and widely cited, independent replication by other research groups is limited. This is a standard scientific concern — not an invalidation of the work, but a reason to interpret the overall evidence base with appropriate caution. ### What doses are used in BPC-157 studies? Animal studies typically use 10 µg/kg or 10 ng/kg body weight (intraperitoneal injection in rats). The few human studies used much higher absolute doses: 4 mg intra-articular (knee), 10 mg intravesical (bladder), and up to 20 mg IV (safety pilot with 2 people). No approved human dosing protocol exists, and animal-to-human dose extrapolation is unreliable for peptides with unknown human pharmacokinetics. ## References 1. **BPC-157 Achilles tendon transection healing** — Journal of Orthopaedic Research — 2003 Early paper describing improved Achilles tendon healing and in-vitro tendocyte stimulation in rats https://pubmed.ncbi.nlm.nih.gov/14554208/ 2. **MCL transection ligament healing with multiple routes** — Journal of Orthopaedic Research — 2010 Rat MCL healing with i.p., topical, and oral administration routes https://pubmed.ncbi.nlm.nih.gov/20225319/ 3. **Colocutaneous fistula healing with NO-system interaction** — Journal of Pharmacological Sciences — 2008 Rat fistula closure with BPC-157 at 10 ug/kg and 10 ng/kg; NO-system interaction tested https://pubmed.ncbi.nlm.nih.gov/18818478/ 4. **Quadriceps transection healing across dose ranges** — Journal of Pharmacological Sciences — 2006 Rat muscle healing at 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. over 72 days https://pubmed.ncbi.nlm.nih.gov/16609979/ 5. **Neuroleptic catalepsy attenuation and gastric ulcer protection** — European Journal of Pharmacology — 1999 BPC-157 attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions in mice/rats https://pubmed.ncbi.nlm.nih.gov/10499368/ 6. **Growth hormone receptor up-regulation in tendon fibroblasts** — Growth Factors — 2014 Cell study showing BPC-157 up-regulates GHR expression with downstream JAK2 activation https://pubmed.ncbi.nlm.nih.gov/25415472/ 7. **Pro-angiogenic mechanism via VEGFR2-Akt-eNOS pathway** — Scientific Reports — 2017 Demonstrated VEGFR2-Akt-eNOS signalling and improved blood flow recovery in rat hind-limb ischaemia https://pubmed.ncbi.nlm.nih.gov/27847966/ 8. **Vasomotor tone and Src-Cav-1-eNOS signalling** — Scientific Reports — 2020 BPC-157 modulates vasomotor tone in isolated aorta via Src-caveolin-1-eNOS pathway https://pubmed.ncbi.nlm.nih.gov/33051481/ 9. **PK/ADME in rats and dogs** — Pharmaceutics — 2022 Pharmacokinetics, biodistribution, and metabolism study including radiolabel distribution and IM bioavailability https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/ 10. **Intra-articular injection for multiple types of knee pain** — Alternative Therapies in Health and Medicine — 2021 Retrospective chart review of 16 patients with intra-articular BPC-157 injections https://pubmed.ncbi.nlm.nih.gov/34324435/ 11. **Intravesical BPC-157 for interstitial cystitis pilot** — Alternative Therapies in Health and Medicine — 2023 Pilot study of 12 women with IC; intravesical injection totaling 10 mg https://www.alternative-therapies.com/oa/pdf/11423.pdf 12. **IV infusion safety pilot (n=2)** — Published 2025 — 2025 IV infusion up to 20 mg in 2 healthy adults; no adverse effects reported https://pubmed.ncbi.nlm.nih.gov/40131143/ 13. **Phase I oral safety/PK trial (NCT02637284)** — ClinicalTrials.gov — 2015 Registered Phase I RCT for oral BPC-157 tablets; unknown status, no posted results https://clinicaltrials.gov/study/NCT02637284 14. **Systematic review: orthopaedic sports medicine perspective** — HSS Journal — 2025 Systematic review noting limited clinical evidence for BPC-157 in orthopaedic applications https://pubmed.ncbi.nlm.nih.gov/40756949/ 15. **Anti-inflammatory effects and cytokine modulation** — Current Pharmaceutical Design — 2018 BPC-157 modulates TNF-α, IL-1β, and IL-6 in inflammatory models including colitis and adjuvant arthritis in rats https://pubmed.ncbi.nlm.nih.gov/29737246/ 16. **Cytoprotective and organoprotective effects** — Medical Science Monitor — 2016 Review of BPC-157 cytoprotection across gastric, hepatic, and multi-organ injury models in rats, framed within Robert's cytoprotection concept https://pubmed.ncbi.nlm.nih.gov/27538397/